News | May 15, 2007

Positive Statistical Analysis from Synthetic Blood's Oxycyte Traumatic Brain Injury Trial

May 16, 2007 — Synthetic Blood International Inc. announced positive data from a statistical analysis of its Phase IIa study with Oxycyte in patients with traumatic brain injury. In line with preliminary study results announced in December 2006, statistical results confirmed that the primary endpoint of increasing patients' oxygen tension levels compared with baseline was met.

Data also show a decrease in patient glucose and lactate/pyruvate (LP) ratio, consistent with increased glucose metabolism. Patients in this trial were stabilized with either 50 percent or 100 percent oxygen. Data determined that results of both treatment arms were favorable, with statistically significant differences in some data between the two treatment arms.

"This analysis further validates our initial study findings that Oxycyte is more effective in increasing brain oxygen tension levels and impacting other brain chemistries that contribute to more favorable clinical outcomes in patients with traumatic brain injury, than breathing either 100 percent or 50 percent oxygen alone," said Robert Nicora, president and CEO. "Based on these positive results, we are working with Virginia Commonwealth University (VCU) to develop a protocol for a multicenter, controlled Phase IIb trial that could enroll up to 100 patients with traumatic brain injury. Researchers at VCU are drafting a manuscript with the Phase IIa TBI results to submit to a scientific journal.

"We continue active discussions with several sources for financing the company," Mr. Nicora continued. "If we are successful in these discussions, the receipt of additional funding will enable us to move forward with our Phase IIb program and other development activities with Oxycyte, which include plans to initiate a cardiac ischemia study in an animal model."

For more information visit www.sybd.com.

Related Content

Artificial Intelligence Performs As Well As Experienced Radiologists in Detecting Prostate Cancer
News | Artificial Intelligence | April 18, 2019
University of California Los Angeles (UCLA) researchers have developed a new artificial intelligence (AI) system to...
Oxipit Introduces Multilingual Support for ChestEye AI Imaging Suite
News | Artificial Intelligence | April 16, 2019
The CE-certified ChestEye artificial intelligence (AI) imaging suite by Oxipit is now available in seven European...
iCAD Appoints Stacey Stevens as President
News | Radiology Business | April 16, 2019
iCAD Inc. recently announced that Stacey Stevens has been named president. As president, Stevens will have expanded...
Enlitic Closes Series B Funding for Artificial Intelligence Solutions for Radiologists
News | Artificial Intelligence | April 08, 2019
Radiology artificial intelligence (AI) company Enlitic announced the close of its $15 million Series B financing round...
iCAD Highlighting ProFound AI for Tomosynthesis at 2019 SBI Annual Symposium
News | Computer-Aided Detection Software | April 04, 2019
iCAD announced it will present its latest artificial intelligence (AI) software solution for digital breast...
A smart algorithm developed by iCAD

A smart algorithm developed by iCAD outlines and scores a suspicious lesion seen in an image created using digital breast tomography. Displayed is the probability calculated by the algorithm that the outlined area includes a cancerous lesion. Image courtesy of Emily Conant, M.D.

Feature | Artificial Intelligence | April 03, 2019 | Greg Freiherr
  Editor's Note: This article was updated following the SBI symposium.  
Siemens Healthineers Debuts AI-Rad Companion Chest CT
News | Artificial Intelligence | January 25, 2019
Siemens Healthineers presented its first intelligent software assistant for radiology, the AI-Rad Companion Chest CT,...
Telerad Tech Launches MammoAssist AI Software
Technology | Computer-Aided Detection Software | January 25, 2019
Telerad Tech recently announced the launch of MammoAssist, a new artificial intelligence (AI) product to analyze and...
Videos | Artificial Intelligence | December 13, 2018
ITN Editor Dave Fornell and ITN Contributing Editor Greg Freiherr share their insights on the vendors showing...
FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis
Technology | Mammography | December 07, 2018
iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer...